SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX:INO), a leader in enabling the development of therapeutic DNA vaccines for cancers and infectious diseases using its electroporation-based delivery platform, announced today that it will host a conference call on Tuesday, January 29, 2008, at 9:00 AM Eastern Standard Time (EST) to update investors about the culmination of the Company’s SECTA program and the five clinical trials that are underway with DNA vaccines. Inovio’s CEO, Dr. Avtar Dhillon, will moderate the call. Interested parties may participate in the conference call by dialing toll-free (877) 407-9210 in the U.S. and Canada, and (201) 689-8049 outside the U.S. and Canada, and entering the conference ID #271013. An audiocast of the conference call will also be made available and may be accessed at the Company’s website, www.inovio.com, and then clicking on “Conference Call.”
